News

State-of-the-art vaccine facility set for Melbourne Airport Business Park

Seqirus, a subsidiary of Victorian-based global biopharmaceutical leader CSL, will invest more than $800 million to build a major new biotech manufacturing facility in Melbourne, worth $300 million to the local supply chain.

The Victorian Government has helped secure the construction of a world-leading Vaccine facility for the state.

The project is a significant investment in Australia by CSL and will position Victoria at the forefront of the global influenza vaccine market.

CSL will invest more than $800 million to build the state-of-the-art facility at the Melbourne Airport Business Park, with operations expected to start in 2026.

The only cell-based influenza vaccine manufacturing facility in the southern hemisphere, the facility will also produce other life-saving products for the Australian market such as the world’s only Q-Fever vaccine and anti-venom for local snakes, spiders and marine creatures.

The Victorian Government is proud to have provided significant support to secure this vital facility in Melbourne, which will support hundreds of jobs and many more in the supply chain,” Minister for Industry Support and Recovery Martin Pakula said.

The project will secure more than 1,000 local jobs, generate export contracts and ensure continuing support for hundreds of organisations estimated to be worth $300 million to the local supply chain, helping to boost the state’s economic recovery.

The new facility will produce seasonal influenza vaccines for use globally and have the capacity to rapidly scale up vaccine production in response to any future influenza pandemic and guarantee the nation with a priority supply.

An agreement between the Commonwealth Government and Seqirus has secured the supply of these products and influenza pandemic protection for Australia over the next 10 years.

“For more than 100 years CSL has been on the front line of the fight against influenza and we are excited to work with Victoria’s world-class talent to deliver the next generation of influenza vaccine technology to Australia,” Seqirus general manager Stephen Marlow said.

 

Send this to a friend